Actinium Pharmaceuticals (NYSEMKT:ATNM) is a cancer-focused biotech that is fundamentally misunderstood due to a perfect storm of "valuation limiting" factors that provide a classic low risk/high reward investment opportunity. The current valuation does not accurately reflect the significant potential licensing opportunities or attractiveness to a larger acquirer given the current M&A environment.
ATNM focuses on the development of cancer drugs based on its proprietary Alpha Particle Immunotherapy platform, which is potentially applicable to a wide variety of cancers. This is a highly potent and selective form of targeted radiotherapy, in which powerful alpha emitting radioisotopes (Actinium 225* or Bismuth 213) are carried by monoclonal antibodies (mAbs) directly to cancer cells.
ATNM has two clinical stage drugs:...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|